2022
Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis
Lansky AJ, Tirziu D, Moses JW, Pietras C, Ohman EM, O'Neill WW, Ekono MM, Grines CL, Parise H. Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis. The American Journal Of Cardiology 2022, 185: 29-36. PMID: 36210212, DOI: 10.1016/j.amjcard.2022.08.032.Peer-Reviewed Original ResearchConceptsHigh-risk percutaneous coronary interventionIntra-aortic balloon pumpPercutaneous coronary interventionAcute kidney injuryCardiogenic shockMyocardial infarctionIABP supportKidney injuryBalloon pumpImproved survivalPropensity adjustmentAcute ST-elevation myocardial infarctionST-elevation myocardial infarctionIndex hospitalization lengthLess myocardial infarctionPremier Healthcare DatabaseHospital myocardial infarctionPropensity-adjusted analysisMechanical circulatory supportMechanical support devicesImpella useHospital survivalIndex hospitalizationCoronary interventionReal-world practice
2020
Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Saito Y, Nazif T, Baumbach A, Tchétché D, Latib A, Kaple R, Forrest J, Prendergast B, Lansky A. Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiology 2020, 5: 92-101. PMID: 31721980, DOI: 10.1001/jamacardio.2019.4367.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementAdjunctive antithrombotic therapyDual antiplatelet therapyAntithrombotic therapyAntiplatelet therapyValve replacementAortic stenosisAortic stenosis (AS) undergoing transcatheter aortic valve replacementSevere symptomatic aortic stenosisSurgical aortic valve replacementGuideline-recommended regimenOral anticoagulant useSevere aortic stenosisSingle antiplatelet therapySymptomatic aortic stenosisPatient risk factorsOngoing clinical trialsRisk prediction modelMajor bleedingOral anticoagulationAnticoagulant useStroke riskTAVR proceduresThrombotic risk
2018
Sex disparities in acute myocardial infarction care and outcomes
Gul B, Kozuma K, Haimi I, Zhao W, Simonton C, Ying S, Buda A, Mehta S, Baumbach A, Lansky A. Sex disparities in acute myocardial infarction care and outcomes. Catheterization And Cardiovascular Interventions 2018, 92: e341-e347. PMID: 29745453, DOI: 10.1002/ccd.27622.Peer-Reviewed Original ResearchMeSH KeywordsAgedChinaClinical Trials as TopicFemaleHealthcare DisparitiesHemorrhageHumansJapanMaleMiddle AgedNon-ST Elevated Myocardial InfarctionPercutaneous Coronary InterventionProduct Surveillance, PostmarketingRegistriesRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsST Elevation Myocardial InfarctionStentsTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsAcute myocardial infarctionPercutaneous coronary interventionTarget vessel failureCause mortalityXience V stentMajor bleedingUS patientsHigher major adverse cardiac eventsSetting of AMIContemporary percutaneous coronary interventionAcute myocardial infarction careDevice-specific outcomesAdverse cardiac eventsMyocardial infarction carePost-market registryCause deathCardiac eventsCoronary interventionMultivariable analysisFemale sexMyocardial infarctionPatient levelSex disparitiesPatients
2015
Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials)
Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, Lansky AJ. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). The American Journal Of Cardiology 2015, 117: 186-191. PMID: 26704028, DOI: 10.1016/j.amjcard.2015.10.029.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionStrong independent predictorMajor bleedingMortality rateBivalirudin therapyCoronary interventionIndependent predictorsFemale genderGlycoprotein IIb/IIIa inhibitor treatmentST-segment elevation myocardial infarctionNon-coronary artery bypassPatient-level pooled analysisImpact of bleedingMajor bleeding ratesPronounced clinical benefitOutcomes of patientsAcute coronary syndromeCohort of patientsElevation myocardial infarctionArtery bypassCoronary syndromeMultivariate adjustmentStandard therapyClinical benefitPooled analysis
2014
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeType C lesionsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsC lesionsLesion complexityBivalirudin monotherapyComposite ischemiaCoronary syndromeCoronary interventionIschemic eventsMyocardial infarctionCardiology/American Heart Association classificationAdverse short-term prognosisAmerican Heart Association classificationAdverse ischemic eventsComposite ischemic eventsContemporary interventional therapyMajor bleeding complicationsMajor hemorrhagic complicationsShort-term prognosisAcute CatheterizationAntithrombotic regimensMajor bleedingSex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial
Yu J, Mehran R, Grinfeld L, Xu K, Nikolsky E, Brodie BR, Witzenbichler B, Kornowski R, Dangas GD, Lansky AJ, Stone GW. Sex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial. Catheterization And Cardiovascular Interventions 2014, 85: 359-368. PMID: 25115966, DOI: 10.1002/ccd.25630.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChi-Square DistributionFemaleHealth Status DisparitiesHemorrhageHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRisk FactorsSex FactorsStentsTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPrimary percutaneous coronary interventionMajor bleedingFemale sexRisk of MACEST-segment elevation myocardial infarction (STEMI) managementGlycoprotein IIb/IIIa inhibitorsAcute Myocardial Infarction trialIIb/IIIa inhibitorsHr of onsetAdverse cardiac eventsMyocardial Infarction trialHigh-risk subsetPresence of comorbiditiesMyocardial infarction managementPercutaneous coronary interventionBare metal stentsSex-based disparitiesFurther dedicated studiesLong-term managementHarmonizing OutcomesCardiac eventsCoronary interventionIschemic eventsSymptom onsetImpact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non–ST-Segment Elevation Acute Coronary Syndromes An Analysis From the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy)
Robertson JO, Ebrahimi R, Lansky AJ, Mehran R, Stone GW, Lincoff AM. Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non–ST-Segment Elevation Acute Coronary Syndromes An Analysis From the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). JACC Cardiovascular Interventions 2014, 7: 372-379. PMID: 24630881, DOI: 10.1016/j.jcin.2013.11.017.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionComorbidityCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionOdds RatioPercutaneous Coronary InterventionProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexSmokingTime FactorsTreatment OutcomeTriageConceptsCoronary artery diseaseMyocardial infarctionACUITY trialMajor bleedingNSTE-ACSArtery diseaseSegment elevation acute coronary syndromesExtent of CADST-segment elevation myocardial infarctionElevation acute coronary syndromeHigh-risk NSTE-ACSSegment Elevation Acute CoronaryDiffuse coronary artery diseaseMyocardial infarction (TIMI) flowAcute coronary syndromeElevation myocardial infarctionPercutaneous coronary interventionPrognosis of patientsPresence of thrombusIncidence of deathLong-term outcomesAcute myocardial infarctionFavorable baseline characteristicsCoronary syndromeNon–ST
2013
Impact of advanced age on the safety and effectiveness of paclitaxel‐eluting stent implantation in patients with ST‐segment elevation myocardial infarction undergoing primary angioplasty
Dudek D, Mehran R, Dziewierz A, Witzenbichler B, Brodie BR, Kornowski R, Fahy M, Lansky AJ, Rakowski T, Legutko J, Bryniarski L, Stone GW. Impact of advanced age on the safety and effectiveness of paclitaxel‐eluting stent implantation in patients with ST‐segment elevation myocardial infarction undergoing primary angioplasty. Catheterization And Cardiovascular Interventions 2013, 82: 869-877. PMID: 23359554, DOI: 10.1002/ccd.24813.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionPaclitaxel-eluting stent implantationPrimary PCIBare metal stentsElevation myocardial infarctionYears of ageStent implantationOlder patientsMyocardial infarctionLower riskIschemic target vessel revascularizationMajor adverse cardiac eventsHORIZONS-AMI studyHORIZONS-AMI trialReduction of MACEAdverse cardiac eventsTarget vessel revascularizationClinical end pointsPercutaneous coronary interventionLong-term resultsImpact of ageCause deathMajor bleedingPrimary angioplastyBleeding Complications in Percutaneous Coronary Interventions
Meier P, Fröhlich GM, Lansky AJ. Bleeding Complications in Percutaneous Coronary Interventions. Cardiology 2013, 125: 213-216. PMID: 23797013, DOI: 10.1159/000351581.Peer-Reviewed Original Research
2011
Radial versus femoral access for primary percutaneous coronary intervention: is there a preferred route to the heart?
Meier P, Windecker S, Lansky AJ. Radial versus femoral access for primary percutaneous coronary intervention: is there a preferred route to the heart? Heart 2011, 98: 269. PMID: 22147901, DOI: 10.1136/heartjnl-2011-301225.Peer-Reviewed Original ResearchLong-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rateImpact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial)
Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108: 1387-1394. PMID: 21864816, DOI: 10.1016/j.amjcard.2011.06.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug UtilizationFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRecombinant ProteinsSmokingStentsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary percutaneous coronary interventionProbable stent thrombosisPercutaneous coronary interventionUnfractionated heparinStent thrombosisMajor bleedingMyocardial infarctionBivalirudin monotherapyCoronary interventionSmoking statusPaclitaxel-eluting stent implantationIIb/IIIa inhibitorsAlternative antithrombotic regimensHORIZONS-AMI trialOutcomes of patientsImpact of smokingPaclitaxel-eluting stentsBare metal stentsLate stent thrombosisAntithrombotic regimensIschemic eventsIndependent predictorsImpact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials
Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, Stone GW. Impact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials. JACC Cardiovascular Interventions 2011, 4: 654-664. PMID: 21700252, DOI: 10.1016/j.jcin.2011.02.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsFemaleHealth Status IndicatorsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial ReperfusionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRandomized Controlled Trials as TopicRecombinant ProteinsRisk AssessmentRisk FactorsTriageConceptsPercutaneous coronary interventionTIMI major bleedingPatient-level pooled analysisHORIZONS-AMI trialMajor bleedingBlood transfusionSubsequent mortalityRisk scoreHazard ratioIndependent predictorsPooled analysisGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsIIb/IIIa inhibitorsMajor bleeding ratesTIMI major bleedTIMI minor bleedingRespective hazard ratiosArtery bypass graftRisk score groupsHigh-risk groupRisk of patientsIsolated hematomasMajor bleedsLate mortalityImpact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions
Palmerini T, Mehran R, Dangas G, Nikolsky E, Witzenbichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Fahy M, Xu K, Brodie B, Lansky A, Stone GW. Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions. Circulation 2011, 123: 2829-2837. PMID: 21632496, DOI: 10.1161/circulationaha.110.985564.Peer-Reviewed Original ResearchConceptsWhite blood cell countPeak creatinine phosphokinase levelCreatinine phosphokinase levelsPercutaneous coronary interventionST-segment elevation acute myocardial infarctionBaseline white blood cell countCoronary interventionAcute myocardial infarctionIndependent predictorsNoncardiac mortalityCardiac mortalityMyocardial infarctionMajor bleedingHigher white blood cell countLower white blood cell countPropensity-adjusted multivariable analysisAcute Myocardial Infarction trialPrimary percutaneous coronary interventionMyocardial Infarction trialVentricular ejection fractionSubgroup of patientsBlood cell countHarmonizing OutcomesCause mortalityEjection fraction
2010
Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient riskA Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes
Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal Of The American College Of Cardiology 2010, 55: 2556-2566. PMID: 20513595, DOI: 10.1016/j.jacc.2009.09.076.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overAngioplasty, Balloon, CoronaryCause of DeathConfidence IntervalsCoronary AngiographyCoronary Artery BypassElectrocardiographyFemaleFibrinolytic AgentsHemorrhageHeparinHospital MortalityHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsProbabilityProportional Hazards ModelsRisk AssessmentSeverity of Illness IndexSurvival AnalysisTreatment OutcomeConceptsAcute coronary syndromeInteger risk scoreMajor bleedingRisk scoreCoronary syndromeNon-coronary artery bypass graft surgerySubsequent mortalityCox proportional hazards regression modelArtery bypass graft surgeryProportional hazards regression modelsMultivariable logistic regression modelHORIZONS-AMI trialPractical risk scoreBypass graft surgerySimple risk scoreIndependent baseline predictorsTreatment-related variablesHazards regression modelsAppropriate treatment strategyLogistic regression modelsGraft surgeryHemorrhagic complicationsIdentifies patientsBlood transfusionLarge hematoma
2009
Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications
Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Circulation 2009, 121: 43-51. PMID: 20026777, DOI: 10.1161/circulationaha.109.878017.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicRecombinant ProteinsRetrospective StudiesRisk FactorsConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsIndividual patient risk profileAcute coronary syndromePatient risk profileMajor bleedingMyocardial infarctionCoronary syndromeRisk profileHemorrhagic complicationsIndependent predictorsMortality rateUrgent Intervention Triage Strategy (ACUITY) trialAlternative antithrombotic regimensIndividual patient's riskRisk of deathCox regression modelTherapy of patientsSubsequent mortality ratesRelative treatment effectsAcute CatheterizationAntithrombotic regimensMajor bleedsAlternative pharmacotherapyStrategy trialBivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implicationsImpact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy
Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, Stone GW. Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy. JACC Cardiovascular Interventions 2009, 2: 748-757. PMID: 19695543, DOI: 10.1016/j.jcin.2009.05.018.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBiomarkersChronic DiseaseCoronary Artery BypassCreatinineDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansKidney DiseasesLogistic ModelsMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaOdds RatioPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsRisk AssessmentTime FactorsTreatment OutcomeTriageConceptsGlycoprotein IIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeBivalirudin monotherapyComposite ischemiaMajor bleedingCoronary syndromeClinical outcomesKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsClinical adverse outcomesCreatinine clearance dataOutcomes of patientsNormal renal functionAdverse event ratesAntithrombotic treatment strategiesSignificant differencesACUITY trialIschemic outcomesRenal functionAdverse outcomesInvasive strategyLate outcomesTreatment strategiesAssociations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial
Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. European Heart Journal 2009, 30: 1457-1466. PMID: 19351691, PMCID: PMC2695951, DOI: 10.1093/eurheartj/ehp110.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeMajor bleedingMyocardial infarctionBaseline predictorsMortality riskMajor bleedsCoronary syndromeHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialElevation acute coronary syndromeMultivariable Cox regression modelsDays of randomizationTime-updated covariatesRecurrent myocardial infarctionIndependent baseline predictorsCox regression modelShort-term riskTiming of mortalityACUITY trialAcute CatheterizationHazard ratioStrategy trialBleedingMortality hazardCox model